Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cell & Molecular Technologies (CMT) was a specialized contract research organization and life sciences tool provider based in New Jersey. The company was best known for its Specialty Media brand, which provided high-quality cell culture media and reagents specifically designed for transgenic research, stem cell biology, and embryo culture. In addition to its product line, CMT offered a range of molecular biology services, including cell line characterization, assay development, and library construction for pharmaceutical and biotechnology clients. The company's expertise in niche media formulations made it a critical partner for researchers in developmental biology and drug discovery. CMT was acquired by Invitrogen Corporation in 2002 for approximately $25 million, and its products were subsequently integrated into the GIBCO and Invitrogen brands under Thermo Fisher Scientific.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cell & Molecular Technologies.